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Abstract: The newest generation of fluoroquinolones have proven efficacy against bacterial 
organisms associated with acute exacerbation of chronic bronchitis (AECB). Gemifloxacin, 
as one of the quinolones in this class, exhibits many of the pharmacokinetic and pharmaco-
dynamic characteristics of the class with a few notable differences. Against Streptococccus 
pneumoniae it has a lower minimal inhibitory concentration (MIC) than the other respiratory 
fluoroquinolones and it has activity against both bacterial DNA gyrase and topoisomerase IV. 
The increased activity of gemifloxacin against both enzymes may be associated with decreased 
rates of resistance. Clinically, gemifloxacin has been shown to have positive effects on length of 
hospitalization and increased success at long-term follow-up in AECB patients. These associa-
tions were observed in noninferiority comparison studies. Although an advantage with the use 
of gemifloxacin in AECB is suggested, there are no comparison data is available to conclude 
that gemifloxacin is superior to the other respiratory fluoroquinolones. Gemifloxacin is gener-
ally well tolerated, but is associated with a characteristic rash and gastrointestinal upset as its 
most common observed side effects.
Keywords: gemifloxacin, respiratory fluoroquinolones, acute exacerbation of chronic 
bronchitis
Introduction
Chronic bronchitis is defined as daily cough and daily production of sputum for at least 
three consecutive months over two consecutive years.1 Most of the patients affected 
by this chronic condition also have underlying nonreversible airflow obstruction, or 
chronic obstructive pulmonary disease (COPD). In most cases the two conditions 
coexist. However, in some cases the chronic cough and sputum production may precede 
the development of airflow limitation.2 In other cases, significant airflow limitation 
may develop without the presence of bronchitic symptoms.1
Chronic bronchitis is generally a slowly progressive disease characterized by 
episodes of acute exacerbation. These exacerbations tend to become more frequent 
and more severe as the underlying disease advances leading to increased morbidity. 
The characteristic symptoms during these episodes are cough, dyspnea and changes 
in sputum volume and purulence. The number of symptoms that are present along 
with the patient’s underlying pulmonary and comorbid diseases help in the classifica-
tion of exacerbating episodes. Most patients have between 1–4 acute exacerbations 
annually.3
The most common risk factors for exacerbation are cigarette smoking, advanced 
age, and low baseline lung function.2 It is a well-known fact that chronic bronchitis International Journal of COPD 2009:4 292
Jivcu and Gotfried Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
and COPD typically develop in long-time smokers as they 
approach middle or old age. These patients, in addition to 
their decreasing lung function, are also at risk for develop-
ing other comorbid conditions either related to smoking or 
advancing age.1 In a 1996 study, 25% of COPD patients over 
65 in the Netherlands had two comorbid conditions and up 
to 17% of had three comorbid conditions.4
The direct correlation between acute exacerbations of 
chronic bronchitis (AECB) and more rapid, permanent 
airway damage is well established. The “vicious circle” of 
acute exacerbations leading to recurrent inflammation and 
eventually to permanent airway damage, which in turn leads 
to more frequent and more profound exacerbations has been 
postulated by Murphy and colleagues5 and later by Wilson.6 
As more data on inflammatory biomarkers became available, 
the same idea was re-explored by Sethi and colleagues.7 
Inflammatory factors such as interleukin-6 (IL-6), C-reactive 
protein, IL-8, and tumor necrosis factor-α have all been 
noted to be elevated during exacerbations. Some of these 
biomarkers, such as procalcitonin, may eventually be useful 
in diagnosis of bacterial causes of AECB in the future.8
Treatment of AECB is multifactorial and it normally 
begins with recommendations regarding lifestyle changes, 
the most important of which without a doubt is smoking 
cessation. Supportive treatment might consist of oxygen 
supplementation in hypoxic patients, removal of environmen-
tal irritants, and appropriate hydration. Pharmaceutical treat-
ment includes inhaled β-agonists, anticholinergics, inhaled 
or systemic corticosteroids, and antibiotic therapy.
The optimal antibiotic therapy for AECB has been 
debated for many decades, and even today it generates con-
siderable debate in the pulmonary community given that only 
select groups of patients have been shown to benefit from 
the therapy. A significant obstacle in achieving consensus 
has been the fact that both patients with stable COPD and 
those with acute exacerbations often grow the same organ-
isms in cultures, and as a result it is difficult to determine 
the exact role of bacteria in the exacerbating events. Follow-
ing Anthonisen and colleagues’ seminal 1987 trial, which 
showed significant response to antibiotic therapy in the 
sickest patients, it has been widely agreed that antibiotics 
should not be withheld from these patients.9
Several medical organizations, including the Canadian 
Thoracic Society (CTS), Canadian Infectious Diseases 
Society (CIDS), and in the US the Primary Care Consensus 
Guidelines among others,10,11 published treatment recom-
mendations for AECB. Among the different recommenda-
tions there is agreement that patients who only have acute 
tracheobronchitis without underlying lung disease should 
be treated supportively without the addition of antibiotics. 
There are differences, however, concerning recommended 
treatment regimens and stratification criteria for patients with 
more severe symptoms, or underlying pulmonary disease. 
Anthonisen’s criteria were based on the number of symptoms 
the patients have, while other criteria proposed by other 
authors also take into consideration the patient’s underlying 
lung disease and comorbidities.12
Infectious agents are thought to cause 80% of exacer-
bations. Of these 50%–70% are estimated to be caused by 
bacterial agents and 30%–50% by viral agents.13 The most 
frequently cultured bacterial agents found during AECB 
continue to remain Haemophilus influenzae, Moraxella 
catarrhalis, and Streptococcus pneumoniae. Others such 
as enterobacter and Pseudomonas species are found in a 
minority of cases, 12%–16% and 5%–9%, respectively.14 The 
most commonly found atypical organism is Chlamydophila 
pneumoniae, while Mycoplasma pneumoniae and Legionella 
pneumophila are rarely isolated.15
Use of fluoroquinolones in AECB
Several recent trials, such as the CAPRIE and MoxiRapid 
trials, have shown that fluoroquinolones are associated with 
superior response in AECB.16,17 In addition, the Council for 
Appropriate and Rational Antibiotic Therapy (CARAT) 
issued a number of guidelines in 2005 to aid physicians in 
appropriate antibiotic selection when treating AECB in the 
outpatient setting. They recommended the use of respiratory 
fluoroquinolones as first-line therapy in the treatment of 
AECB. The rationale for these recommendations included: 
the low rates of resistance, broad-spectrum coverage, high 
respiratory drug concentration and short course therapy. The 
CARAT criteria also recommend higher-dose, short-course 
regimens because they improve convenience and increase 
cost-effectiveness.18
The need for new antibiotics
Prior to the development of the new fluoroquinolones 
increased resistance in Gram-positive organisms against the 
older fluoroquinolones lead to increased effort to develop 
new quinolones with increased activity against these organ-
isms. In Canadian isolates for instance, resistance continues 
to increase among the entire fluoroquinolone class. Rates of 
resistance were 1.8%, 0.7%, 0.6%, and 0.3% to ciprofloxacin, 
levofloxacin, gatifloxacin, and moxifloxacin, respectively19 
in 2002. Overall, the Canadian, TRUST, and PROTEKT US 
data show that S. pnemoniae resistance to flouroquinolones International Journal of COPD 2009:4 293
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is increasing, with current resistance rates ranging between 
0.8%–1.8%.20
Two main strategies have been suggested regarding the 
appropriate response to the apparent increased resistance 
rates of S. pneumoniae to fluoroquinolones. One strategy 
limits exposure by restricting fluoroquinolone use to patients 
who are allergic to β-lactams, have failed first line therapy, 
or have infections with resistant organisms21 thus avoiding 
first line use in many patients. The second strategy pos-
tulates that using the most potent quinolone as a first-line 
agent would reduce the risk of treatment failure (because of 
increased compliance with shorter regimen) and thus reduce 
the emergence of resistance.22
Resistance to fluoroquinolones
Resistance to fluoroquinolones among Gram-positive 
bacteria (such as S. pneumoniae and S. aureus)23 occurs by 
two mechanisms. Alterations in the genes coding for both 
subunits of DNA gyrase (gyrA and gyrB) or topoisomerase 
IV(parC and parE) is the first mechanism and the second is 
through the activity of efflux pumps. The gyrase and topoi-
somerase mutations may coexist. However, parC mutations 
always precede gyrA mutations in S. pneumoniae. Fluoro-
quinolone concentrations that are effective in preventing 
the first mutation (parC) will decrease the development of 
resistance since muations in gyrA do not usually appear in 
the absence of that first step.24
Fluoroquinolone resistance develops by stepwise selection 
of mutations in a region that encodes for the above enzymes, 
also known as the quinolone resistance-determining region 
(QRDR). Target preference varies between different fluo-
roquinolones. Ciprofloxacin and levofloxacin, for instance, 
target topoisomerase IV primarily. Moxifloxacin, on the other 
hand targets DNA gyrase.25 In contrast, gemifloxacin has high 
affinity for pneumococcal topoisomerase IV and an ability to 
inhibit both DNA gyrase and topoisomerase IV.26
Gemifloxacin
Approved by the US Food and Drug Administration (FDA) in 
April 2003, gemifloxacin is a member of the fluoroquinolone 
class that was originally introduced in the 1980s. Typified 
by ciprofloxacin quinolones had good broad spectrum 
activity, including activity against Pseudomonas aeruginosa, 
user-friendly pharmacokinetics allowing twice-daily dosing, 
as well as a benign side-effect profile. Ciprofloxacin’s activity 
against S. pneumoniae was its main shortcoming, with a 
minimal inhibitory concentration (MIC) close to suscep-
tibility breakpoints. Several respiratory fluoroquinolones 
were later introduced with modifications meant to increase 
activity against Gram-positive pathogens.27 Several such 
new agents as grepafloxacin, sparfloxacin, trovafloxacin, 
and gatifloxacin had to be withdrawn from the market due to 
toxicities, but levofloxacin, moxifloxacin, and gemifloxacin 
remain the respiratory fluoroquinolones currently available 
in the United States.
Chemistry
The basic structure for the development of the newer 
quinolones continues to be the nalidixic acid base, with cer-
tain structural modifications to the aromatic core. All the new 
fluoroquinolones retain the 3-carboxyl and ketone groups at 
C-4 from the basic quinolone structure, both of which have a 
role in the binding to the DNA-gyrase complex. Gemifloxa-
cin in particular has a nitrogen in place of the carbon at C-8 
change which is thought to enhance its activity against DNA 
gyrase and topoisomerase IV (Figure 1).28
Pharmacokinetics
The new fluoroquinolones, and by extension gemifloxacin, 
are absorbed rapidly after oral administration with maxi-
mum plasma concentration (Cmax) obtained in 1–3 hours. 
A single 320 mg dose of gemifloxacin yields a peak plasma 
concentration of 1.6 mg/L after one hour. Administration 
with food may delay absorption, however studies by Russo 
and colleagues and Gajjar and colleagues showed that 
overall bioavailability of garenoxacin (des-F(6)-quinolone 
BMS-284756) are equivalent in the fed and fasting states.29,30 
indicating that perhaps fluoroquinolone bioavailability and 
pharmacokinetic properties may not be significantly affected 
by food intake or high fat meals (Table 2).
Penetration of the new flouroquinolones is excellent, 
particularly into alveolar macrophages, bronchial mucosa, 
epithelial lining fluid, and saliva, even though penetration into 
the cerebrospinal fluid (CSF) is limited. Gemifloxacin shows 
similar penetration as other quinolones into saliva, CSF, and 
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Figure 1 Chemical structure of gemifloxacin.International Journal of COPD 2009:4 294
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Table 1 Comparison of in vitro activity of gemifloxacin and other quinolones against the typical ABECB organisms.   Adapted from 
Zhanel GG, Fontaine S,   Adam H, et al.   A review of new fluoroquinolones – focus on their use in respiratory tract infections. Treat Respir 
Med. 2006;5(6):437–465.31 Copyright © 2006, with permission from wolters Kluwer Health pharma Solutions
Antibiotic Streptococcus pneumoniae Haemophilus inluenzae Moraxella catarrhalis
MIC50 MIC90 MIC50 MIC90 MIC50 MIC90
Gemifloxacin 0.03 0.03 0.004 0.008 0.015 0.015
Levofloxacin 1 1 0.015 0.03 0.06 0.06
Ciprofloxacin 1 2 0.004 0.008 0.03 0.03
Moxifloxacin 0.12 0.12 0.03 0.03 0.06 0.06
Abbreviations: MIC50/90, drug concentration inibiting 50% and 90% of the number of strains tested in ug/ml.
inflammatory blister fluid.31 Of note is the comparatively low 
concentration gemifloxacin has in the serum when compared to 
levofloxacin or moxifloxacin (1.4 mg/L vs 4.9mg/L and 3.2 mg/
L, respectively). Despite this, gemifloxacin has achieved bron-
chial mucosa levels and alveolar macrophage levels higher than 
the other two quinolones. Gemifloxacin achieves higher drug 
levels in respiratory tissues than in serum.27
The new fluoroquinolones in addition have a longer half-
life than ciprofloxacin, and all are at least partially eliminated 
through renal pathways. Gemifloxacin and moxifloxacin are 
mostly eliminated by nonrenal pathways. However, dosage 
adjustment for gemifloxacin for renally impaired patients is 
still required.31
Pharmacodynamics
The free 24-hour area under the serum drug concentration/time 
curve (AUC) to MIC ratio is thought to be the major pharma-
codynamic predictor of fluoroquinolone efficacy.27 However, 
the Cmax/MIC ratio may also be predictive, since in human 
studies regarding the activity of levofloxacin the Cmax/MIC ratio 
predicted clinical outcome and microbiologic eradication better 
than AUC/MIC.34 Even clinical trials that showed AUC/MIC 
as the most important parameter, showed that a high Cmax/MIC 
may prevent selection against resistant bacterial strains.35 
For all quinolones the target AUC24/MIC to be achieved 
for Gram-positive coverage in immunocompetent patients 
is 25–30, and in immunocompromised patients 100–125.27 
Like other fluoroquinolones, gemifloxacin is considered to be 
a concentration-dependent bacterial killer and its activity is 
predicted by its ability to reach the target AUC24/MIC. If we 
apply this ratio to evaluate activity against S. pneumoniae we 
find that gemifloxacin achieved a target of 97–127. By com-
parison moxifloxacin achieved a ratio of 96, while ciprofloxacin 
did not reach a ratio of 25.36
Other pharmacodynamic parameters used more recently 
are the postantibiotic effect (PAE) and the mutant prevention 
concentration (MPC). PAE measures the continued 
suppression of bacterial growth after exposure, which means 
that prolonged PAEs protect against bacterial regrowth 
during medication troughs. Given that the PAE of fuoroqui-
nolones is between 1.5–2.5 hours this permits the 12 hour 
or 24 hour dosing of fluoroquinolones.29 Gemifloxacin has 
been shown to have significant in vitro PAE against strains 
of S. pneumoniae and H. influenzae.38,39 The MPC is the drug 
concentration at which selection for resistance is inhibited 
and many of the newer fluoroquinolones can be administered 
safely at concentrations that reach the MPC.40 Gemifloxacin 
was found to have an MPC of 0.13 µg/ml (the lowest of all 
the new fluoroquinolones) against S. pnemunoiae31,32 and 
0.125 µg/ml against H. influenzae.33
Table 2 Summary of the clinical and bacterial efficacy of gemifloxacin versus other agents in the treatment of AECB. Adapted from 
Appelbaum PC, Gillespie SH, Burley CJ, Tillotson GS.   Antimicrobial selection for community-acquired lower respiratory tract infections in 
the 21st century: a review of gemifloxacin. Int J Antimicrob Agents. 2004;23:533–546. Copyright @ 2004, with permission from elsevier
Study Comparator Clinical success in PPP % Bacteriologic success in PPP %
Gemifloxacin Comparator Gemifloxacin Comparator
Ball et al52 None 89.6 91.7
Ball et al6 Trovafloxacin 91.5 87.6 86.8 82.4
wilson et al49 Ceftriaxone/cefuroxime 86.8 81.3 62.5a 60.8a
wilson et al51 Clarithromycin 85.4 84.6 86.7 73.1
File et al51 Amoxicillin/clavulanate 93.6 93.3 90 79.5
Sethi et al54 Levofloxacin 88.2 85.1
Note: a – ITT population
Abbreviation: PPP per-protocol populationInternational Journal of COPD 2009:4 295
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In their assessment of pharmacokinetic–pharmacodynamic 
(PK–PD) target attainment of gemifloxacin against 
S. pneumoniae in a simulated population of 2500 patients 
in 2005, Owens and colleagues analyzed the probability of 
attaining fAUC/MIC (24-hour free AUC/MIC) ratio based 
on data from two sources.41 First Owens used a population 
pharmacokinetic model and second, an MIC distribution 
based on 3317 S. pneumoniae isolates was used. The prob-
ability of attaining fAUC/MIC ratio was 0.79 for levofloxacin 
and 0.98 for gatifloxacin. In another analysis the probability 
was 85.8% for levofloxacin and 99.3% for moxifloxacin. 
The probability of reaching the PK–PD target for gemi-
floxacin “over the entire pneumococcal MIC distribution was 
greater than 0.99.” Owens and collegues concluded that in 
regions where increased incidence of levofloxacin-resistant 
pneumococci has been recorded, such as the western United 
States, it might be prudent to use more potent agents like 
gemifloxacin instead of the less potent levofloxacin since 
gemifloxacin has a higher probability of reaching the intended 
pharmacodynamic and pharmacokinetic targets.
In vitro activity
A number of in vitro studies done over the last few years 
compared the activity of new and old fluroquinolones against 
the typical respiratory organisms associated with AECB. 
Table 1 contains the results of some several in vitro studies as 
well as the MIC50 and MIC90 for ciprofloxacin, levofloxacin, 
moxifloxacin, and gemifloxacin. In all cases gemifloxacin has 
a lower MIC than the other fluoroquinolones.
In a 2004 study, Pereyre and colleagues compared 
garenoxacin (a des-fluoro quinolone unavailable in the 
United States), gatifloxacin and gemifloxacin with four other 
quinolones: moxifloxacin, levofloxacin, ciprofloxacin, and 
ofloxacin.42 These antibiotics were tested against 31 strains 
of Mycoplasma pneumonieae, 40 strains of M. hominis, 
46 strains of Ureaplasma and 9 strains of M. fermentans. 
Of the new fluoroquinolones garenoxacin and gemifloxacin 
had the highest activity against quinolone-resistant strains of 
both Mycoplasma and Ureaplasma with MICs of 1 µg/ml 
for all strains with one mutation and most of the strains with 
two mutations.
In 2005, Pankuch and colleagues tested the activity of 
five quinolones (ciprofloxacin, levofloxacin, gatifloxacin, 
moxifloxacin, and gemifloxacin), three macrolides 
(erythromycin, azithromycin, and clarithromycin), and 
telithromycin against 12 H. influenzae strains.43 All quinolones 
were active against all 12 strains tested regardless of 
the β-lactam or macrolide resistance.
In 2005, an in vitro study in Saudi Arabia tested 
ciprofloxacin, ofloxacin, gemifloxacin, grepafloxacin, 
trovafloxacin, and levofloxacin against the most common 
bacteria associated with AECB.44 Eighty-eight isolates of 
S. pneumoniae, 116 strains of H. influenzae, and 80 strains 
of M. catarrhalis were used in the comparison. The authors 
found that S. pneumoniae isolates were fully susceptible 
to trovafloxacin, grepafloxacin, and gemifloxacin while 
susceptibility to ofloxacin and levofloxacin was 97.7% and 
98.9%. H. influenzae was susceptible to all agents except 
trovafloxacin (99.1%) and M. catarrhalis was susceptible to 
all agents except ofloxacin (97.5%). None of these isolates 
were resistant to gemifloxacin.
In 2006, De Azavedo and colleagues tested serotype 6B of 
the BCP2443 strain of S. pneumoniae against gemifloxacin, 
gatifloxacin, and goxifloxacin.45 This isolate is resistant to 
erythromycin and intermittently resistant to penicillin, but 
fully susceptible to all fluoroquinolones and has no known 
quinolone resistance-determining region (QRDR) mutations. 
They found that gemifloxacin showed 2- to 16-fold greater 
activity than moxifloxacin or gatifloxacin against strains with 
two or more QRDR mutations.
Finally, in 2007, La Plante and colleagues analyzed the 
association between fAUC/MIC ratio and the development 
of resistance of wildtype S. pneumoniae to gatifloxacin, 
gemifloxacin, levofloxacin, and moxifloxacin.46 They found 
that gatifloxacin, gemifloxacin, and moxifloxacin exceeded 
the fAUC/MIC resistance breakpoint against S. pneumoniae. 
They also found that the order of resistance development 
determined from fAUC/MIC breakpoints was levofloxacin  
gatifloxacin  moxifloxacin = gemifloxacin. These results 
show that moxifloxacin and gemifloxacin have optimal 
in vitro activity against wildtype S. pnumoniae, and suggest 
that their use may decrease the emergence of resistance in 
S. pneumoniae.
Animal studies
Animal studies done to compare gemifloxacin with other 
respiratory antibiotics and other fluoroquinolones continue 
the same trend seen in the in vitro results, showing better 
clinical response after treatment with gemifloxacin versus 
some of the older and newer fluoroquinolones, as well as 
versus other antibiotics commonly used against respiratory 
pathogens.
Berry and colleagues tested gemifloxacin in the rat 
respiratory tract infection against four strains of S. pneumoniae 
and two strains of H. influenzae and compared it with 
amoxicillin–clavulanate, ciprofloxacin, cefuroxime, azithro-International Journal of COPD 2009:4 296
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mycin, trovafloxacin, grepafloxacin, and levofloxacin.47 Their 
results showed that gemifloxacin was as effective as amoxicil-
lin–clavulanate, and more potent than all others against the 
strains of S. pneumoniae. Gemifloxacin was significantly 
more potent than cefuroxime and azithromycin against the 
H. influenzae strains.
In the Swiss White mouse model Bast and colleagues 
compared two-day and five-day courses of gemifloxacin 
versus levofloxacin in the treatment of pneumococcal 
pneumonia.48 Survival rates for gemifloxacin were 83%–100% 
compared with 40%–58% for levofloxacin.
Clinical studies
Several noninferiority clinical trials comparing gemifloxacin 
to other antibiotics used in the treatment of AECB have been 
completed since gemifloxacin’s introduction in 2003, however 
so far only two compared gemifloxacin with other fluoroquino-
lones. Although these noninferiority trials were not designed to 
highlight the difference between gemifloxacin and comparator 
antibiotics, a few differences should be noted.
In our review we found three studies that compared 
gemifloxacin with ceftriaxone/cefuroxime, clarithromycin 
and amoxicillin/clavulanate respectively. In 2003, Wilson 
and colleagues compared the activity of gemifloxacin with 
that of IV ceftriaxone/oral cefuroxime in the treatment 
of 271 hospitalized patients with AECB.49 The clinical 
success rates at follow-up were 86.8% for gemifloxacin 
vs. 81.3% for ceftriaxone/cefuroxime in the entire study 
population (treatment difference = 5.5; 95% confidence 
interval [CI]: -3.9, 14.9). In the clinical intention-to-treat 
(ITT) population the clinical results were 82.6% vs. 72.1% 
(95% CI: 0.7, 20.4). Time to discharge for the gemifloxacin 
group was nince days while for the IV/oral β-lactam group 
was 11 days. This decrease in time of hospitalization in the 
gemifloxacin group was statistically significant (p = 0.04.)
In another British noninferiority trial, 712 patients 
with Anthonisen type I AECB symptoms (increased dys-
pnea, cough, and sputum purulence) were randomized to 
treatment with five days of gemifloxacin (n = 351) versus 
seven days of clarithromcin (n = 361).50 The long-term 
phase of the study (26 weeks) evaluated the percentage of 
patients who remained free of AECB and did not require 
reinitiation of antibiotic treatment. Clinical success rates 
were 85.4% for gemifloxacin and 84.6% for clarithromycin 
at the 2–3 week follow-up. Bacteriologic success rates 
were 86.7% for gemifloxacin versus 73.1% for clarithro-
mycin. In addition, in the gemifloxacin group 71% of 
patients remained free of AECB symptoms at the 26-week 
follow-up, versus 58.5% for clarithromycin (p = 0.016). 
Of note in this study is that a significantly shorter time to 
H. influenzae eradication was noted in the gemifloxacin 
group versus the clarythromycin group (p = 0.02): no 
H. influenzae was recovered from the gemifloxacin group 
after one day of treatment, while 50% were recovered from 
the clarithromycin group.
In a 2000 comparison study done in the United States, 
File and colleagues compared gemifloxacin with amoxicil-
lin/clavulanate for the treatment of AECB.51 The clinical 
success rates were comparable at 93.6% for gemifloxacin 
versus 93.2% for amoxicillin/clavulanate. The bacteriologi-
cal success rate of gemifloxacin however was significantly 
higher: 90.0% versus 79.5% difference which achieves 
statistical significance (95% CI: -3.3 to 26.0).
In the two studies that compared gemifloxacin with 
another fluoroquinolone, gemifloxacin showed higher clinical 
success rates versus trovafloxacin and levofloxacin respec-
tively. In 2001, Ball and colleagues published a prospective, 
randomized, double-blind, double dummy, parallel, 
multicenter comparison of gemifloxacin with trovafloxacin 
in 617 randomized patients with AECB.52 The clinical suc-
cess rates were 91.5% for gemifloxacin versus 87.6% for 
trovafloxacin. In the ITT population, clinical success was 
89% for gemifloxacin versus 83% for trovafloxacin, which 
was statistically significant (95% CI: -1.2, 9.0). Clinical 
recurrence rates at long-term follow-up were 8.8% for gemi-
floxacin versus 10.5% for trovafloxacin.
In a second study, this time an open-label, noncom-
parative study, Ball and colleagues assessed the clinical 
efficacy of gemifloxacin in AECB and community-acquired 
pneumonia (CAP) and reported clinical success of 83.1% at 
follow-up and bacteriologic success (ITT) of 91.2%.53 Total 
eradication rates exceeded 90% in this study including eradi-
cation of H. influenzae, M. catarrhalis, and S. pneumoniae 
(S. pneumoniae was eradicated in all cases).
Finally in 2004, Sethi and colleagues compared the 
clinical efficacy of gemifloxacin versus levofloxacin in 
360 patients with AECB in their randomized, double-
blind, double dummy, multicenter, parallel group study.54 
Clinical success rate in the protocol population was 88.2% 
for gemifloxacin and 85.1% for levofloxacin. In the ITT 
population the clinical success rate was 85.2% for gemifloxa-
cin versus 78.1% for levofloxacin. At long-term follow-up 
(days 28–35) the gemifloxacin success rate was 83.7% versus 
78.4% for levofloxacin, which is a clinically significant 
finding (95% CI: -3.83, 14.34), and fewer patients withdrew 
from the gemifloxacin group than the levofloxacin group International Journal of COPD 2009:4 297
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(seven patients vs 18 patients, respectively, which was also 
statistically significant; p = 0.02).
These clinical trials, although intended to show the 
noninferiority of gemifloxacin, identified some clini-
cally significant differences between gemifloxacin and 
comparator drugs: decreased length of hospitalization 
versus ceftriaxone/cefuroxime;49 shorter time to eradica-
tion of H. influenzae when compared with clarithromycin;50 
increased bacteriological success rate in AECB when com-
pared to amoxicillin/clavulanate.51 More importantly for our 
purposes of comparing gemifloxacin with other fluoroquino-
lones, gemifloxacin had a higher clinical success rate when 
compared to trovafloxacin,52 and a higher rate of success 
versus levofloxacin at long-term follow-up54 in two high 
quality trials (both trials get high scores on Jadad scale).55
Clinical tolerability
The most common adverse reactions to fluoroquinolones are 
mild and consist of gastrointestinal (GI) symptoms, central 
nervous system (CNS) symptoms, and skin symptoms.31 
Gastrointestinal reactions include nausea, vomiting, and 
diarrhea. Nausea is the most common GI symptom and is 
more common with gatifloxacin and moxifloxacin rang-
ing between 6%–10%, while vomiting and diarrhea range 
between 1%–6% and appear to be similar among the newer 
fluoroquinolones. CNS adverse reactions have been reported 
with all fluoroquinolones and consist mainly of headaches 
and dizziness. These reactions have been reported to be 
2%–3% for gatifloxacin and moxifloxacin versus 1% for 
gemifloxacin and levofloxacin.
Gemifloxacin has been associated with 2.8%–4.8% 
incidence of hypersensitivity reactions (rash and pruritus), 
which is the highest rate of all the new fluoroquinolones 
as opposed to 1% for the others. These reactions are most 
common in women aged younger than 40 years as well as in 
postmenopausal women taking estrogen replacement.31 The 
rash was also associated with length of duration of therapy, 
usually noticed on regimen longer than seven days.27
Photosensitivity has also been reported with several 
fluoroquinolones and the associated skin changes consist 
of erythema, edema, desquamation and rarely painful 
blistering. In the case of gemifloxacin, phototoxicity 
appears to be dose-related and resolves within 48 hours after 
treatment is stopped. Photoxocity has not been reported with 
moxifloxacin or gatifloxacin.
QT prolongation is a well-reported adverse reaction to 
fluoroquinolones. A retrospective database analysis for the 
period 1996–2001 in the USA has found 25 cases of torsades 
de pointes (Tdp)56 associated with use of fluoroquinolones. 
However, the proarrhythmic potential is not the same for all 
fluoroquinolones. Moxifloxacin seems to have the greatest risk 
of QT prolongation, while gemifloxacin, ciprofloxacin, and 
ofloxacin seem to have less risk. The overall risk of developing 
Tdp is low at less than that of macrolides57,58 however, current 
recommendations still advise caution in prescribing fluoroqui-
nolones to patients who are taking other medications that may 
prolong the QT interval. Electrocardiogram monitoring is not 
necessary in all patients, but should be done in patients who 
have underlying conditions that may cause QT prolongation 
or who take other pharmaceuticals that may cause it.59
Hepatotoxicity, characterized by increased aspartate 
aminotransferase and alanine aminotransferase 1.5 times 
baseline has been reported in 4.1% of patiens on gemi-
floxacin. Moxifloxacin was associated with 2.5%–3.8% 
hepatotoxicity.31
Several cases of arthralgias have been reported in 
association with fluoroquinolones in children, but there is no 
evidence of decreased linear growth in treated children. Most 
of the children treated with respiratory fluoroquinolones 
have cystic fibrosis. The rate of treatment related arthralgia 
was no greater than the rate in nontreated cystic fibrosis 
patients.31
Tendinopathy is another rare but well-documented 
class effect with fluoroquinolones. In 90% of the reported 
cases of tendinopathy, the Achilles tendon was the injured 
tendon. Risk factors include concurrent therapy with 
corticosteroids or hemodialysis, or the presence of renal 
dysfuction, post-renal transplant, and rheumatic diseases.31 
A recent boxed warning about tendinopathy was added to 
all fluoroquinolone package inserts.60
Economics
A cost analysis of the GLOBE study data evaluated the 
cost effectiveness of gemifloxacin versus clarithromycin 
in the treatment of AECB. In their analysis, Halpern and 
colleagues found that of the patients treated with gemifloxa-
cin 73.8% did not have recurrence of AECB versus 63.8% 
of the clarithromycin group (p = 0.024).61 Fewer patients 
on gemifloxacin therapy were hospitalized than patients on 
clarithromycin therapy (2.33% versus 6.25%; p = 0.059). 
The mean direct cost for a patient on gemifloxacin was 
US$247 versus US$347 for a patient on clarithromycin. This 
represents a 29% difference in mean direct cost. The mean 
direct and indirect costs for a patient on gemifloxacin was 
US$1,413 versus US$1,742 for a patient on clarithromycin, 
or a 19% difference in indirect costs.International Journal of COPD 2009:4 298
Jivcu and Gotfried Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
In 2003, Wilson and colleagues showed that the time to 
hospital discharge for the gemifloxacin group was nine days, 
while the time for the IV/oral β-lactam group was 11 days 
(p = 0.04.).50 In addition, clinical success rates at follow-up 
(21–28 days post therapy) of 86.8% for gemifloxacin versus 
81.3% for ceftriaxone/cefuroxime (95% CI: -3.9, 14.9) 
indicate a possible lower frequency of treatment failure. 
These findings suggest that gemifloxacin can result in cost 
savings when compared to the comparators ceftriaxone/oral 
cefuroxime, and clarithromycin.
Conclusion
Gemifloxacin is a new fluoroquinolone with proven efficacy 
against respiratory bacteria associated with AECB. In vitro 
and clinical studies show that gemifloxacin is not inferior to 
the other respiratory fluoroquinolones, and may have some 
potential advantages. It has a lower MIC than other new fluo-
roquinolones against the typical pathogens in AECB; it has 
dual activity against DNA gyrase and topoisomerase IV, and it 
has been associated with decreased emergence of resistance in 
S. pneumoniae. Clinically it has been associated with decreased 
length of hospitalization when compared to ceftriaxone and 
clarithromycin (and as a result with decreased health care 
costs) and higher rate of success versus levofloxacin at long-
term follow-up. Gemifloxacin has a slightly higher incidence 
of hepatotoxicity and hypersensitivity reactions than other new 
fluoroquinolones, while it appears to have a lower incidence 
of gastrointestinal and CNS symptoms. In conclusion, gemi-
floxacin seems to be an effective quinolone in the treatment 
of AECB, however further studies comparing gemifloxacin 
with other respiratory quinolones are needed to determine any 
possible superiority. Its long-term benefit could be based on a 
theoretic ability to decrease emergence of quinolone resistance 
in respiratory pathogens. A well characterized rash on top of 
other known quinolone side effects can occur.
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